Since the launch of its SmartSlide Micro-Incubation System in late 2006, WaferGen has seen a positive response from many leading research institutions and organizations. The company's current SmartSlide(TM) Micro-Incubation System customers include Harvard University, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, Abbott Labs, the National Institutes of Health (NIH), and several leading pharmaceutical companies.
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip(TM) is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide(TM), which was launched in 2006, represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research. Representative SmartSlide(TM) customers include Harvard University, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, Abbott Labs, and the National Institutes of Health (NIH).
To learn more about WaferGen, please visit the company's web site at http://www.wafergen.com.
Safe Harbor Statement under the Private Securities Litigation Refo
|SOURCE WaferGen Biosystems, Inc.|
Copyright©2008 PR Newswire.
All rights reserved